Cullinan Therapeutics reports initial Phase 1 CLN-978 data in refractory SLE and RA

 

Cullinan Therapeutics reports initial Phase 1 CLN-978 data in refractory SLE and RA showing clinical benefit and favorable safety

• CLN-978 is a CD19xCD3 T cell engager evaluated in refractory systemic lupus erythematosus and rheumatoid arthritis.
• Phase 1 data presented at the EULAR 2026 Congress demonstrated clinical benefit, including remissions in treated patients.
• Treatment produced deep, dose-dependent B cell depletion, supporting CLN-978 biological activity in these refractory autoimmune diseases.
• Single and initial multi-dose regimens showed a favorable safety profile in this early-stage study.

https://finviz.com/stock?t=CGEM&p=d